Last checked at 26 Dec 2023 19:41
Wall Street gains on final stretch of 2023, rate cuts in view
Intel up on $3.2 bln grant from Israel
*Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Astrazeneca Share News (AZN)
AZN Share
Price
AZN Share
News1
AZN Share
Chat
AZN Share
Trades
AZN
Live RNS
AZN Share
Charts
AZN Level 2
Console
AZN Live
Share Price
AZN Broker
Ratings
AZN Directors
Deals
AZN Financial
Diary
AZN
Fundamentals
AZN Short
Positions
AZN
Media
Astrazeneca Information
Share Price Information for Astrazeneca (AZN)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
12,364.00
Bid:
11,850.00
Ask:
12,470.00
Change:
0.00 (0.00%)
Spread:
620.00 (5.232%)
Open:
0.00
High:
0.00
Low:
0.00
Prev. Close:
12,364.00
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.AstraZeneca offloads rights to Nexium and Vimovo
Mon, 03rd Dec 2018 07:25
(Sharecast News) - AstraZeneca has completed an agreement to divest the prescription medicine rights to Nexium (esomeprazole) in Europe, as well as the global rights - excluding the US and Japan - to Vimovo (naproxen/esomeprazole), to Grunenthal, it announced on Monday.The FTSE 100 pharmaceuticals giant said that under the terms of the agreement, it received payments of $700m for Nexium and $115m for Vimovo from Grunenthal.It said the upfront payments, net of an appropriate derecognition of an intangible asset related to Vimovo, would be reported within 'other operating income and expense' in its financial statements in the fourth quarter of 2018.AstraZeneca said it would continue to commercialise Nexium in all markets outside Europe, where it retained the rights.It would not retain any ownership rights to Vimovo globally."The book value of gross assets subject to the divestments was approximately $99m at 31 December 2017," the AstraZeneca board explained in its statement."In the year to 31 December 2017 the aggregate pre-tax profits attributable to Nexium and Vimovo in the relevant territories were $203m."The consideration will be satisfied in cash and the proceeds used for general corporate purposes."
More News
22 Dec 2023 08:47
AstraZeneca, Ionis get US FDA nod for Wainua in "important milestone"
(Alliance News) - AstraZeneca PLC and Ionis Pharmaceuticals Inc on Friday celebrated the news that their drug eplontersen was approved by the US Food & Drug Administration.
Read more22 Dec 2023 07:50
LONDON BRIEFING: UK on brink of recession as economy contracts in Q3
(Alliance News) - Stocks in London are likely to open lower on Friday, with investors feeling frosty ahead of a US inflation print this afternoon, amid sobering UK economic growth data.
Read more22 Dec 2023 07:17
AstraZeneca gets FDA green light for nerve disease treatment
(Sharecast News) - The US Food and Drug Administration has approved the Wainua nerve disease treatment jointly developed by AstraZeneca and Ionis Pharmaceuticals.
Read more19 Dec 2023 19:56
US adds 13 companies in China to Unverified List
WASHINGTON, Dec 19 (Reuters) - The United States has added 13 companies in China to a list of entities receiving U.S. exports that officials have been unable to inspect, according to a government notice posted on Tuesday.
Read more15 Dec 2023 17:14
London stocks log weekly gains as cenbank fest ends
FTSE 100 down 1.0%, FTSE 250 off -0.3%
*Read more15 Dec 2023 16:51
LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools
(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.
Read more15 Dec 2023 16:29
PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg
(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.
Read more13 Dec 2023 17:07
UK's FTSE 100 rises as pound slips on GDP data; awaits Fed rate decision
UK economy shrinks by 0.3% in October
*Read more12 Dec 2023 16:00
London close: Stocks slip as investors digest US inflation
(Sharecast News) - London's markets finished in the red on Tuesday, as investors digested a slight decrease in consumer inflation in the US, while the UK's unemployment figures remained stable.
Read more12 Dec 2023 12:07
London midday: FTSE still firmer ahead of US inflation print
(Sharecast News) - London's markets remained relatively stable by midday on Tuesday, with the top-flight index still in the green after fresh jobs data showed a slowdown in wage growth.
Read more12 Dec 2023 10:08
AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal
Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.
Read more12 Dec 2023 08:53
LONDON MARKET OPEN: FTSE 100 opens higher ahead of US CPI
(Alliance News) - Stock prices in London opened higher on Tuesday, as investors digest the latest UK unemployment data, before turning their eyes to US inflation this afternoon.
Read more12 Dec 2023 08:37
AstraZeneca acquires vaccine developer Icosavax for USD1.1 billion
(Alliance News) - AstraZeneca PLC confirmed on Tuesday that it will buy Icosavax Inc, boosting its vaccine portfolio with an "innovative" treatment for respiratory viruses.
Read more12 Dec 2023 07:39
LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI
(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.
Read more